US2002019515A1PendingUtilityA1

Novel spoIIIE

41
Priority: Aug 26, 1997Filed: Feb 2, 2001Published: Feb 14, 2002
Est. expiryAug 26, 2017(expired)· nominal 20-yr term from priority
Inventors:Alison Frances ChalkerMaria Magdalena Zalacain FeliuJames Raymond BrownAlexander Bryant
A61P 9/00A61P 27/00A61P 25/00A61P 31/00A61P 31/04A61P 1/00C07K 14/31A61P 13/00A61P 11/00A61P 17/00A61P 19/00A61K 39/00
41
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides spoIIIE polypeptides and DNA (RNA) encoding spoIIIE polypeptides and methods for producing such polypeptides by recomombinant techniques. Also provided are methods for utilizing spoIIIE polypeptides to screen for antibacterial compounds.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . An isolated polypeptide comprising a fragment of SEQ ID NO:2 comprising at least 50 consecutive amino acids of SEQ ID NO:2 ; wherein said fragment has chromosomal partitioning activity.  
     
     
         2 . A composition comprising the isolated polypeptide of  claim 1  and a carrier.  
     
     
         3 . The isolated polypeptide of  claim 1 , wherein the isolated polypeptide comprises a heterologous amino acid sequence fused to the at least 50 consecutive amino acids of SEQ ID NO:2.  
     
     
         4 . A composition comprising the isolated polypeptide of  claim 3  and a carrier.  
     
     
         5 . An isolated polypeptide comprising a fragment of SEQ ID NO:2 comprising at least 30 consecutive amino acids of SEQ ID NO:2; wherein said fragment has chromosomal partitioning activity.  
     
     
         6 . A composition comprising the isolated polypeptide of  claim 5  and a carrier.  
     
     
         7 . The isolated polypeptide of  claim 5 , wherein the isolated polypeptide comprises a heterologous amino acid sequence fused to the at least 30 consecutive amino acids of SEQ ID NO:2.  
     
     
         8 . A composition comprising the isolated polypeptide of  claim 7  and a carrier.  
     
     
         9 . An isolated polypeptide comprising a fragment of SEQ ID NO:2 comprising at least 50 consecutive amino acids of SEQ ID NO:2; wherein said fragment has the ability to generate antibodies to SEQ ID NO:2.  
     
     
         10 . A composition comprising the isolated polypeptide of  claim 9  and a carrier.  
     
     
         11 . The isolated polypeptide of  claim 9 , wherein the isolated polypeptide comprises a heterologous amino acid sequence fused to the at least 50 consecutive amino acids of SEQ ID NO:2.  
     
     
         12 . A composition comprising the isolated polypeptide of  claim 11  and a carrier.  
     
     
         13 . An isolated polypeptide comprising a fragment of SEQ ID NO:2 comprising at least 30 consecutive amino acids of SEQ ID NO:2; wherein said fragment has the ability to generate antibodies to SEQ ID NO:2.  
     
     
         14 . A composition comprising the isolated polypeptide of  claim 13  and a carrier.  
     
     
         15 . The isolated polypeptide of  claim 13 , wherein the isolated polypeptide comprises a heterologous amino acid sequence fused to the at least 30 consecutive amino acids of SEQ ID NO:2.  
     
     
         16 . A composition comprising the isolated polypeptide of  claim 15  and a carrier.

Join the waitlist — get patent alerts

Track US2002019515A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.